Blazek M - Search Results

1

Selectins and monocyte chemotactic peptide as the markers of atherosclerosis activity.

Bláha M, Krejsek J, Bláha V, Andrýs J, Vokurková D, Malý J, Blazek M, Skorepová M. Bláha M, et al. Among authors: blazek m. Physiol Res. 2004;53(3):273-8. Physiol Res. 2004. PMID: 15209534 Free article. Clinical Trial.

2

Primary hemostasis in patients treated with LDL-apheresis for severe familiar hypercholesterolemia: a prospective pilot trial using PFA-100 analysis to rationalize therapeutic LDL-apheresis procedure.

Blazek M, Blaha M, Pecka M, Blaha V, Masin V, Maly J. Blazek M, et al. Hematology. 2007 Dec;12(6):571-6. doi: 10.1080/10245330701448370. Hematology. 2007. PMID: 17852459

3

Activity of thrombocytes as a marker of sufficient intensity of LDL-apheresis in familial hypercholesterolaemia.

Blaha M, Pecka M, Urbankova J, Blaha V, Maly J, Zadak Z, Blazek M. Blaha M, et al. Among authors: blazek m. Transfus Apher Sci. 2004 Apr;30(2):83-7. doi: 10.1016/j.transci.2003.11.002. Transfus Apher Sci. 2004. PMID: 15062743

4

Safety and tolerability of long lasting LDL-apheresis in familial hyperlipoproteinemia.

Bláha M, Cermanová M, Bláha V, Blazek M, Malý J, Siroký O, Solichová D, Filip S, Rehácek V. Bláha M, et al. Among authors: blazek m. Ther Apher Dial. 2007 Feb;11(1):9-15. doi: 10.1111/j.1744-9987.2007.00450.x. Ther Apher Dial. 2007. PMID: 17309569

5

Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia.

Blaha M, Cermanova M, Blaha V, Jarolim P, Andrys C, Blazek M, Maly J, Smolej L, Zajic J, Masin V, Zimova R, Rehacek V. Blaha M, et al. Among authors: blazek m. Atherosclerosis. 2008 Mar;197(1):264-70. doi: 10.1016/j.atherosclerosis.2007.04.022. Epub 2007 May 30. Atherosclerosis. 2008. PMID: 17540382 Clinical Trial.

6

Extracorporeal LDL cholesterol elimination (25 years of experience in CZ).

Blaha M, Zadak Z, Blaha V, Andrys C, Havel E, Vyroubal P, Blazek M, Filip S, Lanska M, Maly J. Blaha M, et al. Among authors: blazek m. Atheroscler Suppl. 2009 Dec 29;10(5):17-20. doi: 10.1016/S1567-5688(09)71804-5. Atheroscler Suppl. 2009. PMID: 20129368

7

[Changes in hemostasis in malignant diseases].

Malý J, Blazek M, Bláha M, Pecka M. Malý J, et al. Among authors: blazek m. Vnitr Lek. 2002 Jul;48(7):614-8. Vnitr Lek. 2002. PMID: 12197402 Review. Czech.

8

The importance of rheological parameters in the therapy of microcirculatory disorders.

Bláha M, Rencová E, Bláha V, Malý R, Blazek M, Studnicka J, Andrýs C, Fátorová I, Filip S, Kasparová M, Procházková R, Malý J, Zimová R, Langrová H. Bláha M, et al. Among authors: blazek m. Clin Hemorheol Microcirc. 2009;42(1):37-46. doi: 10.3233/CH-2009-1184. Clin Hemorheol Microcirc. 2009. PMID: 19363239 Clinical Trial.

9

Haemorheopheresis could block the progression of the dry form of age-related macular degeneration with soft drusen to the neovascular form.

Rencová E, Bláha M, Studnička J, Blažek M, Bláha V, Dusová J, Malý J, Kyprianou G, Vašátko T, Langrová H. Rencová E, et al. Among authors: blazek m. Acta Ophthalmol. 2011 Aug;89(5):463-71. doi: 10.1111/j.1755-3768.2009.01710.x. Epub 2010 Jan 22. Acta Ophthalmol. 2011. PMID: 20102350 Free article. Clinical Trial.

10

[Influence of haemorheopheresis in the dry form of the age related macular degeneration].

Rencová E, Bláha M, Blazek M, Bláha V, Studnicka J, Dusová J, Solichová D, Kyprianou G, Langrová H. Rencová E, et al. Among authors: blazek m. Cesk Slov Oftalmol. 2009 Apr;65(2):43-8. Cesk Slov Oftalmol. 2009. PMID: 19408858 Clinical Trial. Czech.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101 results

Search Page

Filters